# Exelixis, Inc. – Consensus ‘buy’ rating and 31.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc.consensus-buy-rating-and-31.4-upside-potential/4121130952
- Published: 2023-10-26T13:24:00+01:00
- Author: Charlotte Edwards

**Exelixis, Inc.** which can be found using ticker (EXEL) have now 17 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between 32 and 18 with the average target price sitting at
$25.76. Now with the previous closing price of $19.61 and the analysts are correct
then we can expect a percentage increase in value of 31.4%. Also worth taking note
is the 50 day moving average now sits at $21.66 and the 200 day MA is $19.46. The
market capitalization for the company is 6.33B. The stock price for the company 
is currently 19.88 USD

 The potential market cap would be $8,314,415,867 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 39.76, revenue per share of 5.3 
and a 2.93% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on: